---
title: "Humacyte gets Nasdaq notice after shares trade below $1 bid-price minimum"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294555524.md"
description: "Humacyte received a Nasdaq notice for failing the $1 minimum bid price rule, as shares closed below $1 for 30 consecutive business days ending July 30, 2026. The company has until January 27, 2027, to regain compliance by maintaining a closing bid of at least $1 for 10 consecutive business days. The notice does not immediately affect trading on the Nasdaq Global Select Market under the ticker HUMA."
datetime: "2026-07-31T21:01:24.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294555524.md)
  - [en](https://longbridge.com/en/news/294555524.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294555524.md)
generator: "portal-rs"
---

# Humacyte gets Nasdaq notice after shares trade below $1 bid-price minimum

-   Humacyte received a Nasdaq notice for failing the $1 minimum bid rule, with shares closing below $1 for 30 consecutive business days ended July 30, 2026. \* The company has until Jan. 27, 2027 to regain compliance by posting a closing bid of at least $1 for 10 consecutive business days. \* The notice does not immediately affect trading on the Nasdaq Global Select Market under HUMA. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Humacyte Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-089281), on July 31, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [HUMA.US](https://longbridge.com/en/quote/HUMA.US.md)
- [HUMAW.US](https://longbridge.com/en/quote/HUMAW.US.md)

## Related News & Research

- [Humacyte director Keith Anthony Jones reports purchase of 10,000 common shares worth $6,930](https://longbridge.com/en/news/296648477.md)
- [Humacyte director Keith Anthony Jones acquires 30,000 shares worth $17,820](https://longbridge.com/en/news/296394198.md)
- [Humacyte says Phase 3 V007 trial results show ATEV tops fistula for hemodialysis access at one year](https://longbridge.com/en/news/296352370.md)
- [Humacyte Faces Nasdaq Non-Compliance Warning as Share Price Risks Delisting and Future Capital Constraints](https://longbridge.com/en/news/295900197.md)
- [22:00 ETHumacyte Investigation Continued: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Humacyte, Inc. - HUMA](https://longbridge.com/en/news/296662242.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**